Stay updated on Pembrolizumab for HNSCC Residual Disease Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for HNSCC Residual Disease Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The NIH banner announcing terminology changes from “Artificial Intelligence” to “Super Intelligence” was removed. The page continues to show a 403 error instead of the study record.
    Difference
    1%
    Check dated 2026-11-08T03:10:31.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer now identifies the site as revision v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-31T23:14:40.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A banner was added announcing NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T23:09:53.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The site footer revision number changed from v3.7.1 to v3.7.2; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T23:36:03.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The footer site revision changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T23:28:59.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, making the study record inaccessible. The prior study documents and related navigation have been removed, leaving only the error message and site footer.
    Difference
    19%
    Check dated 2026-09-19T22:23:40.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for HNSCC Residual Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.